Download - Dr. Yusra Hipertensi Unizar-1
![Page 1: Dr. Yusra Hipertensi Unizar-1](https://reader034.vdocument.in/reader034/viewer/2022042603/563db9e7550346aa9aa0f991/html5/thumbnails/1.jpg)
Yusra Pintaningrum
![Page 2: Dr. Yusra Hipertensi Unizar-1](https://reader034.vdocument.in/reader034/viewer/2022042603/563db9e7550346aa9aa0f991/html5/thumbnails/2.jpg)
![Page 3: Dr. Yusra Hipertensi Unizar-1](https://reader034.vdocument.in/reader034/viewer/2022042603/563db9e7550346aa9aa0f991/html5/thumbnails/3.jpg)
![Page 4: Dr. Yusra Hipertensi Unizar-1](https://reader034.vdocument.in/reader034/viewer/2022042603/563db9e7550346aa9aa0f991/html5/thumbnails/4.jpg)
WHO 1999
![Page 5: Dr. Yusra Hipertensi Unizar-1](https://reader034.vdocument.in/reader034/viewer/2022042603/563db9e7550346aa9aa0f991/html5/thumbnails/5.jpg)
JNC VII
![Page 6: Dr. Yusra Hipertensi Unizar-1](https://reader034.vdocument.in/reader034/viewer/2022042603/563db9e7550346aa9aa0f991/html5/thumbnails/6.jpg)
ETIOLOGY
![Page 7: Dr. Yusra Hipertensi Unizar-1](https://reader034.vdocument.in/reader034/viewer/2022042603/563db9e7550346aa9aa0f991/html5/thumbnails/7.jpg)
MECHANISM OF PRIMARY
HEMODYNAMIC SUBTYPE
![Page 8: Dr. Yusra Hipertensi Unizar-1](https://reader034.vdocument.in/reader034/viewer/2022042603/563db9e7550346aa9aa0f991/html5/thumbnails/8.jpg)
Neurohormonal control of blood pressure
Blood pressure = Cardiac output (CO) x Peripheral resistance (PR)
Hypertension = Increased CO and/or Increased PR
Preload
Fluid volume
Renal sodiumretention
Contractility
Fluid volume
Vasoconstriction
Sympatheticnervoussystem
Renin-angiotensin-aldosterone
system
Geneticfactors
Excesssodiumintake
(Adapted from Kaplan, 1994)
![Page 9: Dr. Yusra Hipertensi Unizar-1](https://reader034.vdocument.in/reader034/viewer/2022042603/563db9e7550346aa9aa0f991/html5/thumbnails/9.jpg)
Acute neurohormonal effects on blood pressure homeostasis
Acute neurohormonal effects on blood pressure homeostasis
Heart rate and cardiac output
Perfusion
Sodium and water retention
Blood pressure
RAA SNS
![Page 10: Dr. Yusra Hipertensi Unizar-1](https://reader034.vdocument.in/reader034/viewer/2022042603/563db9e7550346aa9aa0f991/html5/thumbnails/10.jpg)
Chronic neurohormonal effects on vascular structure
Chronic neurohormonal effects on vascular structure
Myocardial hypertrophy
Perfusion
Glomerular hypertention and hypertrophy
Vascular hypertrophy
RAA SNS
![Page 11: Dr. Yusra Hipertensi Unizar-1](https://reader034.vdocument.in/reader034/viewer/2022042603/563db9e7550346aa9aa0f991/html5/thumbnails/11.jpg)
Haemodynamic Transition from Hyperkinetic to Typical Essential Hypertension
Cardiaccompliance
Beta adrenergicresponsiveness
Strokevolume Heart rate
CARDIAC OUTPUT
Wall/lumenratio
Endothelialdamage
Vaso-constriction Vasodilation
VASCULAR RESISTANCE
HEART RESISTANCE ARTERIOLES
![Page 12: Dr. Yusra Hipertensi Unizar-1](https://reader034.vdocument.in/reader034/viewer/2022042603/563db9e7550346aa9aa0f991/html5/thumbnails/12.jpg)
PATOPHYSIOLOGY
The factors affecting cardiac output: - sodium intake, renal function, & mineralocorticoids - the inotropic effects occur via extracellular fluid volume augmentation - an increase in heart rate and contractility
Peripheral vascular resistance is dependent upon the sympathetic nervous system, humoral factors, and local autoregulation
(Sharma, 2003)
![Page 13: Dr. Yusra Hipertensi Unizar-1](https://reader034.vdocument.in/reader034/viewer/2022042603/563db9e7550346aa9aa0f991/html5/thumbnails/13.jpg)
NEURAL MECHANISM
![Page 14: Dr. Yusra Hipertensi Unizar-1](https://reader034.vdocument.in/reader034/viewer/2022042603/563db9e7550346aa9aa0f991/html5/thumbnails/14.jpg)
VASCULAR MECHANISM
![Page 15: Dr. Yusra Hipertensi Unizar-1](https://reader034.vdocument.in/reader034/viewer/2022042603/563db9e7550346aa9aa0f991/html5/thumbnails/15.jpg)
HORMONAL MECHANISM
![Page 16: Dr. Yusra Hipertensi Unizar-1](https://reader034.vdocument.in/reader034/viewer/2022042603/563db9e7550346aa9aa0f991/html5/thumbnails/16.jpg)
Diagnosis Approach
![Page 17: Dr. Yusra Hipertensi Unizar-1](https://reader034.vdocument.in/reader034/viewer/2022042603/563db9e7550346aa9aa0f991/html5/thumbnails/17.jpg)
![Page 18: Dr. Yusra Hipertensi Unizar-1](https://reader034.vdocument.in/reader034/viewer/2022042603/563db9e7550346aa9aa0f991/html5/thumbnails/18.jpg)
"The Goal is to Get to Goal!”
Hypertension -PLUS- Diabetes or Renal Disease
< 140/90 mmHg < 130/80 mmHg
Patients should return for follow-up and adjustment of medications every 1-2 months until the BP goal is reached
![Page 19: Dr. Yusra Hipertensi Unizar-1](https://reader034.vdocument.in/reader034/viewer/2022042603/563db9e7550346aa9aa0f991/html5/thumbnails/19.jpg)
Algorithm for Treatment of Hypertension
Not at Goal Blood Pressure (<140/90 mmHg) (<130/80 mmHg for those with diabetes or chronic kidney disease)
Initial Drug Choices
Drug(s) for the compelling indications
Other antihypertensive drugs (diuretics, ACEI, ARB, BB, CCB)
as needed.
With Compelling Indications
Lifestyle Modifications
Stage 2 HTN (SBP >160 or DBP >100 mmHg)
2-drug combination for most (usually thiazide-type diuretic and
ACEI, or ARB, or BB, or CCB)
Stage 1 HTN (SBP 140–159 or DBP 90–99 mmHg)
Thiazide-type diuretics for most. May consider ACEI, ARB, BB, CCB, or
combination.
Without Compelling Indications
JNC 7 Express. JAMA. 2003 Sep 10; 290(10):1314
Not at Goal Blood Pressure
Optimize dosages or add additional drugs until goal blood pressure is achieved.
Consider consultation with hypertension specialist.
![Page 20: Dr. Yusra Hipertensi Unizar-1](https://reader034.vdocument.in/reader034/viewer/2022042603/563db9e7550346aa9aa0f991/html5/thumbnails/20.jpg)
![Page 21: Dr. Yusra Hipertensi Unizar-1](https://reader034.vdocument.in/reader034/viewer/2022042603/563db9e7550346aa9aa0f991/html5/thumbnails/21.jpg)
![Page 22: Dr. Yusra Hipertensi Unizar-1](https://reader034.vdocument.in/reader034/viewer/2022042603/563db9e7550346aa9aa0f991/html5/thumbnails/22.jpg)
![Page 23: Dr. Yusra Hipertensi Unizar-1](https://reader034.vdocument.in/reader034/viewer/2022042603/563db9e7550346aa9aa0f991/html5/thumbnails/23.jpg)
![Page 24: Dr. Yusra Hipertensi Unizar-1](https://reader034.vdocument.in/reader034/viewer/2022042603/563db9e7550346aa9aa0f991/html5/thumbnails/24.jpg)
![Page 25: Dr. Yusra Hipertensi Unizar-1](https://reader034.vdocument.in/reader034/viewer/2022042603/563db9e7550346aa9aa0f991/html5/thumbnails/25.jpg)
![Page 26: Dr. Yusra Hipertensi Unizar-1](https://reader034.vdocument.in/reader034/viewer/2022042603/563db9e7550346aa9aa0f991/html5/thumbnails/26.jpg)
![Page 27: Dr. Yusra Hipertensi Unizar-1](https://reader034.vdocument.in/reader034/viewer/2022042603/563db9e7550346aa9aa0f991/html5/thumbnails/27.jpg)
![Page 28: Dr. Yusra Hipertensi Unizar-1](https://reader034.vdocument.in/reader034/viewer/2022042603/563db9e7550346aa9aa0f991/html5/thumbnails/28.jpg)
![Page 29: Dr. Yusra Hipertensi Unizar-1](https://reader034.vdocument.in/reader034/viewer/2022042603/563db9e7550346aa9aa0f991/html5/thumbnails/29.jpg)
Follow-up and Monitoring
Patients should return for follow-up and adjustment of medications every 1-2 months until the BP goal is reached
After BP at goal and stable, follow-up visits at 3- to 6-month intervals More frequent visits for stage 2 HTN or with
complicating comorbid conditions Continue to encourage self BP monitoring
Serum potassium and creatinine monitored 1–2 times per year
JNC 7 Express. JAMA. 2003 Sep 10; 290(10):1314